DHAKA, Oct 12 (Reuters) - Bangladesh launched a nationwide vaccination campaign on Sunday to protect millions of children from typhoid, a deadly and increasingly drug-resistant disease that poses a ...
PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj. ® Multi-dose is manufactured ...
A new vaccine against salmonella and typhoid moves closer to approval, according to results of a clinical trial published by researchers at the University of Maryland School of Medicine Oct. 8. “These ...
Typhoid fever, an illness that has been controlled in developed countries since the early 20th century, is evolving to be antibiotic-resistant. Research published in 2022 shows that typhoid is ...
Hosted on MSN
Typhoid conjugate vaccine demonstrates strong safety and immunogenicity in Phase III trial
Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it is safe and immunogenic in typhoid-endemic populations in sub-Saharan Africa ...
Hosted on MSN
Bangladesh launches nationwide typhoid vaccine campaign, aiming to cover 50 million children
, Oct. 12 -- The government of Bangladesh, with support from UNICEF, Gavi, the Vaccine Alliance, and WHO, on Sunday officially launched the nationwide Typhoid Conjugate Vaccine (TCV) campaign. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results